General Information:

Id: 3,890 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Fatty liver disease, nonalcoholic
Insulin resistance
Metabolic syndrome
Reference: Matikainen N and Taskinen MR(2012) Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes Curr Cardiol Rep 14: 721-731 [PMID: 22941588]

Interaction Information:

Comment Analysis of prospective outcome studies involving 170,000 subjects demonstrates a robust beneficial effect of statins in CHD prevention in subgroups with diabetes, elevated systolic blood pressure, low HDL-C, and elevated BMI which all are components of MetS.
Formal Description
Interaction-ID: 39327

drug/chemical compound


decreases_activity of


Coronary artery disease

in subjects with diabetes, elevated systolic blood pressure, low HDL, and elevated BMI